Canada in-vitro Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 3.86 Billion |
| Market Size (2029) | USD 4.92 Billion |
| CAGR (2024 - 2029) | 4.98 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Canada in-vitro Diagnostics Market Analysis
The Canada In-vitro Diagnostics Market size is estimated at USD 3.86 billion in 2024, and is expected to reach USD 4.92 billion by 2029, growing at a CAGR of 4.98% during the forecast period (2024-2029).
The emergence of the SARS-CoV-2 virus has increased lab testing demands to keep pace with suspected cases of COVID-19. Thus, the recent outbreak of COVID-19 has had a positive impact on the in-vitro diagnostics industry, as it involves the testing of various biological samples. Likewise, the growing need for early diagnosis of COVID-19 patients provided lucrative opportunities for the key players to expand their geographical reach within the country and has led to new product launches and approvals. For instance, in February 2021, Thermo Fisher Scientific received Health Canada authorization for its Applied Biosystems TaqPath COVID-19 HT Kit, to give a significant boost to laboratories' COVID-19 testing capabilities. Thus, such developments are likely to bolster the growth of the in-vitro diagnostics market in the country.
Moreover, the factors that are responsible for the growth of this market include the increasing use of point-of-care (POC) diagnostics; advanced technologies; and increasing awareness and acceptance of personalized medicine and companion diagnostics.
In-vitro diagnostics products and consumables are extremely valuable for disease prevention, detection, and management. The demand for point-of-care diagnostics is increasing owing to the high burden of various diseases in this country. According to the data published by GLOBOCAN 2020, it was estimated that in 2020, approximately 274,364 Canadians were diagnosed with cancer. Likewise, as per the 2022 report from the Public Health Agency of Canada (PHAC), there were 604 cases of monkeypox as of July 20, 2022. Therefore, the rising cases of these infectious diseases will help boost the demand for in-vitro diagnostics to aid in the diagnosis or detection of these diseases, in turn driving the market growth.
In addition, the emerging technological innovations in healthcare, such as biosensors, lab-on-a-chip, wearable devices, and point of care (POC) diagnostics, are increasingly becoming an important part of the healthcare landscape. POC diagnostics are no longer limited to simple tests and can now be used for diagnosing serious conditions. Market players in this region are focusing on market development strategies such as product development, merger and acquisition, and partnerships. For instance, in March 2021, QIAGEN N.V. launched the QIAcube Connect MDx, a flexible platform for automated sample processing for molecular diagnostic laboratories in Canada. Also, in April 2020, Seegene, Inc. received the Health Canada (HC) authorized interim order which allows the import and sale in Canada of Seegene's Allplex 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease.
Thus, owing to all these market development strategies, coupled with the growing burden of several diseases in the country, the market for in-vitro diagnostics is expected to grow in Canada. However, stringent regulations and cumbersome reimbursement procedures are likely to hinder the market's growth.
Canada in-vitro Diagnostics Market Trends
Reagent Segment is Expected to hold the Significant Market Share Over the Forecast Period
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Reagents are an integral part of the in-vitro diagnostics testing procedure. They are used for a wide variety of disease diagnoses. With the increasing complexity of diseases and demand for early diagnosis, there is an increased use of complex reagent combinations in laboratories to diagnose these diseases from biological samples. In addition, for the assessment of a patient's general health by a physician, the major information comes from the information supplied by the diagnostics laboratory, where the importance of diagnostic reagents becomes evident. Many diagnostic companies have an excess of more than 50% of sales from consumables, such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
Furthermore, increasing competition, pressures laboratories to continuously improve quality and provide rapid results, this demand drives the need for reagents that perform multiple functions efficiently. For instance, in May 2021, LaunchWorks, a contract development and manufacturing organization (CDMO) in molecular diagnostics, and Canadienzyme, a Canadian biotech spin-off company, entered into a collaboration to produce a new RT-qPCR Master Mix, an RT-qPCR testing reagent.
Thus, these factors are likely to drive the demand for the reagents segment throughout the forecast period.
Canada in-vitro Diagnostics Industry Overview
The Canadian In-Vitro Diagnostics market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. In addition, the rising need for diagnostics due to the rising prevalence of diseases and the advances in IVD is helping a few other smaller players enter the market. Some of the major players in the market are Becton Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, and Thermo Fisher Scientific, among others.
Canada in-vitro Diagnostics Market Leaders
-
Bio-Rad Laboratories Inc.
-
Danaher Corporation
-
Siemens Healthineers
-
Abbott Laboratories
-
Becton, Dickinson and Company
*Disclaimer: Major Players sorted in no particular order
Canada in-vitro Diagnostics Market News
- In May 2022, BioMérieux received Health Canada approval for the BioFire Blood Culture Identification 2 (BCID2) panel for rapid identification of bloodstream infections. The BCID2 panel includes additional pathogens, an expanded list of antimicrobial resistance genes, and revised targets compared to the original BCID panel.
- In January 2022, Yourgene, the international molecular diagnostics group, launched its new expanded facility named "Yourgene Health Canada Inc." in Canada.
Canada in-vitro Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumption and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Use of Point-of-Care (POC) Diagnostics and Advancements in Technology
- 4.2.2 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
-
4.3 Market Restraints
- 4.3.1 Stringent Regulations and Cumbersome Reimbursement Procedures
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Test Type
- 5.1.1 Clinical Chemistry
- 5.1.2 Molecular Diagnostics
- 5.1.3 Hematology
- 5.1.4 Immuno Diagnostics
- 5.1.5 Other Tests
-
5.2 By Product
- 5.2.1 Instrument
- 5.2.2 Reagent
- 5.2.3 Other Products
-
5.3 By Usability
- 5.3.1 Disposable IVD Devices
- 5.3.2 Reusable IVD Devices
-
5.4 By Application
- 5.4.1 Infectious Disease
- 5.4.2 Diabetes
- 5.4.3 Cancer/Oncology
- 5.4.4 Cardiology
- 5.4.5 Autoimmune Disease
- 5.4.6 Nephrology
- 5.4.7 Other Applications
-
5.5 By End Users
- 5.5.1 Diagnostic Laboratories
- 5.5.2 Hospitals and Clinics
- 5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Siemens AG
- 6.1.2 Danaher Corporation
- 6.1.3 F. Hoffmann-La Roche AG
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 Bio-Rad Laboratories Inc.
- 6.1.6 Abbott Laboratories
- 6.1.7 Arkray Inc.
- 6.1.8 Hologic, Inc
- 6.1.9 Thermo Fischer Scientific Inc.
- 6.1.10 Qiagen N.V.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCanada in-vitro Diagnostics Industry Segmentation
As per the scope of the report, in-vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases. The Canada In-vitro market is segmented by Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, Immuno Diagnostics, and Other Tests), Product (Instrument, Reagent, and Other Products), Usability (Disposable IVD Devices and Reusable IVD Devices), Application, (Infectious Diseases, Diabetes, Cancer/Oncology, Cardiology, Autoimmune Disease, Nephrology, and Other Applications), and End Users (Diagnostic Laboratories, Hospitals and Clinics, and Other End Users). The report offers the value (in USD) for the above segments.
| By Test Type | Clinical Chemistry |
| Molecular Diagnostics | |
| Hematology | |
| Immuno Diagnostics | |
| Other Tests | |
| By Product | Instrument |
| Reagent | |
| Other Products | |
| By Usability | Disposable IVD Devices |
| Reusable IVD Devices | |
| By Application | Infectious Disease |
| Diabetes | |
| Cancer/Oncology | |
| Cardiology | |
| Autoimmune Disease | |
| Nephrology | |
| Other Applications | |
| By End Users | Diagnostic Laboratories |
| Hospitals and Clinics | |
| Other End Users |
Canada in-vitro Diagnostics Market Research FAQs
How big is the Canada In-vitro Diagnostics Market?
The Canada In-vitro Diagnostics Market size is expected to reach USD 3.86 billion in 2024 and grow at a CAGR of 4.98% to reach USD 4.92 billion by 2029.
What is the current Canada In-vitro Diagnostics Market size?
In 2024, the Canada In-vitro Diagnostics Market size is expected to reach USD 3.86 billion.
Who are the key players in Canada In-vitro Diagnostics Market?
Bio-Rad Laboratories Inc., Danaher Corporation, Siemens Healthineers, Abbott Laboratories and Becton, Dickinson and Company are the major companies operating in the Canada In-vitro Diagnostics Market.
What years does this Canada In-vitro Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Canada In-vitro Diagnostics Market size was estimated at USD 3.67 billion. The report covers the Canada In-vitro Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Canada In-vitro Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Canada in-vitro Diagnostics Industry Report
Statistics for the 2024 Canada in-vitro Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Canada in-vitro Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
